Cymbalta
Product Images NDC 43353-303

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 43353-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 30mg (43353 303)

This is a description of a medication called Duloxetine HCI (Cymbalta) DR 30mg 3060 Capsules. The medicine should be kept between 20-25 degrees Celsius (63-77 degrees Fahrenheit) and stored in a light-resistant container per USP regulations. The manufacturing of the medicine is done by Eli Lilly and Company in Indianapolis whereas the repackaging is done by Aphen Pharma in Cookeville with the NDC# 43353-0303-19. The text possibly includes batch or lot numbers as well but they are not readable by .*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (Cymbalta 01)

FDA Label Image

Figure 1 (Cymbalta 02)

FDA Label Image

Figure 2 (Cymbalta 03)

FDA Label Image

Figure 3 (Cymbalta 13)

FDA Label Image

Figure 4 (Cymbalta 14)

FDA Label Image

Figure 5 (Cymbalta 15)

This is a graph showing the percentage of patients improved with the CYM60/120 mg once daily medication and placebo. The x-axis represents the percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. The graph shows that more patients improved with the medication compared to placebo.*

FDA Label Image

Figure 6 (Cymbalta 16)

The given text represents a graph showing the percentage of patients improved on placebo and CYMB0 (a medication) mg once daily. The percentage of improvement is plotted against the percentage improvement in pain from baseline (BOCF). The x-axis represents the percentage improvement in pain from baseline, and the y-axis represents the percentage of patients improved. The graph shows that more patients improved with CYMB0 mg than with placebo.*

FDA Label Image

Figure 7 (Cymbalta 17)

This is a graph that displays the percentage of patients who improved with placebo and Cymbalta at 120 mg once daily treatment. The x-axis shows different levels of percent improvement in pain from baseline and the y-axis shows the number of patients. It seems that the percentage of patients who improved is 100%, and the graph shows a comparison between the placebo and Cymbalta treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.